Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TT-00920 MAD Study in Healthy Subjects
NCT05043792Phase 1Completed
- Sponsor
- TransThera Biosciences
- Start
- Aug 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TT-00920 in chronic heart failure (CHF) and heart failure with preserved ejection fraction (HFpEF) (3 arms), sponsored by TransThera Biosciences. Primary endpoint: Treatment-Emergent Adverse Events at 14 days. Started Aug 2021; status: completed.
02
Drugs
TT-00920
03
Conditions
chronic heart failure (CHF)heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT05043792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05043792.